WASHINGTON, April 27 (Reuters) - Outgoing Valeant
Pharmaceuticals Chief Executive Michael Pearson plans
to tell a U.S. Senate panel on Wednesday that he regrets his
decision to acquire and jack up the price of two life-saving
heart drugs, saying it was all a "mistake."
Read more
No comments:
Post a Comment